Cytokinetics (NASDAQ:CYTK) Given Equal Weight Rating at Morgan Stanley
Morgan Stanley reiterated their equal weight rating on shares of Cytokinetics (NASDAQ:CYTK – Free Report) in a research report report published on Friday, Marketbeat reports. The firm currently has a $90.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $60.00. Several other equities research analysts have also recently issued […]
More Stories
CMC Metals (CVE:CMB) Stock Price Down 25% – Should You Sell?
CMC Metals Ltd. (CVE:CMB – Get Free Report) shares traded down 25% on Friday . The stock traded as low...
Plus500 (LON:PLUS) Sets New 1-Year High – Should You Buy?
Plus500 Ltd. (LON:PLUS – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Friday ....
Avrupa Minerals (CVE:AVU) Hits New 1-Year Low – Should You Sell?
Avrupa Minerals Ltd. (CVE:AVU – Get Free Report)’s share price reached a new 52-week low during trading on Friday ....
MTB Metals (CVE:MTB) Reaches New 12-Month Low – Here’s What Happened
MTB Metals Corp. (CVE:MTB – Get Free Report) hit a new 52-week low during mid-day trading on Friday . The...
Beijing Capital International Airport Company Limited (OTCMKTS:BJCHF) Sees Significant Drop in Short Interest
Beijing Capital International Airport Company Limited (OTCMKTS:BJCHF – Get Free Report) saw a large drop in short interest in December....
Babcock International Group PLC (OTCMKTS:BCKIF) Sees Large Decline in Short Interest
Babcock International Group PLC (OTCMKTS:BCKIF – Get Free Report) was the recipient of a significant decline in short interest in...